BONESUPPORT™ Announces Key Corporate Appointment To Drive Growth In North America

LUND, Sweden, November 7, 2016 /PRNewswire/ --

BONESUPPORT AB, an emerging leader in innovative injectable bioceramic bone graft substitutes to treat bone voids caused by trauma, infection, disease or related surgery, is pleased to announce the appointment of Patrick O'Donnell as General Manager and Executive Vice President, North American Commercialization to its leadership team. Mr O'Donnell will lead the relationship with the company's partner, Zimmer Biomet, to drive revenue growth of BONESUPPORT's CERAMENT™ BONE VOID FILLER (BVF). He will also set the strategy for the introduction of CERAMENT™ G, a novel gentamicin eluting bone graft substitute, to the U.S. market pending a positive outcome of the planned FORTIFY PMA trial and subject to FDA approval.

Mr O'Donnell joins BONESUPPORT after serving as CEO of three companies focused on innovative orthopaedic regenerative technologies. Following his role as CEO of Histogenics Corporation, he was most recently the Co-Founder and CEO of ProteoThera Inc., based in Cambridge, MA. His experience includes being head of Global Marketing of Confluent Surgical, where he launched and built the DuraSeal™ brand of surgical dural sealant products, currently owned by Integra LifeSciences In addition, he spent 13 years in sales, sales management and marketing in orthobiologics and medical devices at Johnson & Johnson's DePuy Spine Division.

Mr O'Donnell said: "I am very pleased about the opportunity and quite fortunate to be joining BONESUPPORT at a very important and exciting tipping point stage for the Company. I look forward to working with the BONESUPPORT team to optimize the significant potential of CERAMENT BVF and in time CERAMENT G in North America."

Richard Davies, CEO of BONESUPPORT, said: "We are excited to welcome Patrick to the BONESUPPORT team, particularly after completing the recent financing, which will be crucial to executing our strategy. Patrick brings with him a great breadth of experience ranging from start-ups to small and large companies. He has an in-depth of knowledge of the orthobiologics space and appreciation of the significant potential of our unique CERAMENT drug eluting osteoconductive bioceramic platform to develop a pipeline of novel products for a broad range of bone diseases. The clinical value proposition of our products is expected to become increasingly relevant to the U.S. healthcare market which is undergoing a sea change to value based care."

- Ends -

Notes to Editor 

About BONESUPPORT™  

BONESUPPORT has developed CERAMENT as an innovative range of radiopaque injectable osteoconductive bioceramic products that have a proven ability to heal defects by remodeling to host bone in six to twelve months. Our products are effective in treating patients with fractures and bone voids caused by trauma, infection, disease or related surgery. Our lead product, CERAMENT BONE VOID FILLER (BVF) addresses important issues facing health care providers, such as avoiding hospital readmissions and revision surgery that result from failed bone healing and infection caused by residual bone voids. CERAMENT BVF is commercially available in the U.S., EU, SE Asia and the Middle East.

CERAMENT's distinctive properties as a drug eluting material have been validated in clinical practice by CERAMENT G and CERAMENT V, the first CE-marked injectable antibiotic eluting bone graft substitutes. These products provide local sustained delivery of gentamicin and vancomycin, respectively. The local delivery feature enables an initial high concentration of antibiotics to the bone defect and then a longer sustainable dose above the minimal inhibitory concentration (MIC) to protect bone healing and promote bone remodeling.

CERAMENT G and CERAMENT V have demonstrated good results in patients with problematic bone infections including osteomyelitis. They are also used prophylactically in patients who are at risk for developing infection. CERAMENT G and CERAMENT V are available in the EU.

BONESUPPORT was founded in 1999 by Prof. Lars Lidgren, an internationally respected scientist who has been the President of various musculoskeletal societies. BONESUPPORT's mission is to bring people with bone and joint diseases back to an active life. The Company is based in Lund, Sweden. www.bonesupport.com

BONESUPPORT™ is a registered trademark. 

Contact Information

Citigate Dewe Rogerson
David Dible, Andrea Bici, Mark Swallow
+44 (0)20 7282 2949/1050/2948
bonesupport@citigatedr.co.uk